Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Share-based Compensation (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Share-based Compensation for 14 consecutive years, with $283000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 87.42% to $283000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $649000.0, a 66.15% decrease, with the full-year FY2025 number at $576000.0, down 80.23% from a year prior.
  • Share-based Compensation was $283000.0 for Q4 2025 at Aytu Biopharma, up from $114000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.1 million in Q4 2022 to a low of $113000.0 in Q2 2025.
  • A 5-year average of $878894.7 and a median of $900000.0 in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 233.85% in 2021, then plummeted 85.55% in 2025.
  • Aytu Biopharma's Share-based Compensation stood at $1.2 million in 2021, then surged by 149.55% to $3.1 million in 2022, then crashed by 73.26% to $820000.0 in 2023, then crashed by 81.59% to $151000.0 in 2024, then skyrocketed by 87.42% to $283000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Share-based Compensation are $283000.0 (Q4 2025), $114000.0 (Q3 2025), and $113000.0 (Q2 2025).